Current Research Studies

Research Studies and Clinical Trials

  • Search for "progressive supranuclear palsy", "corticobasal degeneration", or "multiple system atrophy".

  • The purpose of this study is to determine the safety and tolerability (maximum tolerated dose (MTD) within planned dosing range) of intravenous (IV) infusions of TPI-287 administered once every 3 weeks for 9 weeks (for a total of 4 infusions) in patients with primary four repeat tauopathies (4RT), corticobasal syndrome (CBS) or progressive supranuclear palsy (PSP).

  • The purpose of this study is to better understand why individuals with Progressive Supranuclear Palsy (PSP) fall. Understanding the mechanism of gait and balance dysfunction in individuals with PSP may provide us with important early diagnostic tools, allowing for earlier identification of mobility problems and to better evaluate medical therapies aimed at improving motor disability.

  • The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE). This combination should result in enhanced orthostatic release of NE. The investigators have already demonstrated that pyridostigmine does not raise supine blood pressure.

  • The purpose of this study is to identify structural and functional changes in the brain using non-invasive neuroimaging techniques to develop sensitive and specific markers for each of these diseases, and then to track how these markers change as each disease progresses to a 2 year time point.

  • The goal of this study is to identify the best methods of analysis for tracking PSP and CBD over time. The results from this study may be used in the future to calculate power for clinical drug trials, as this study aims to identify the most reliable outcome measures.

  • Conducted mainly at Vanderbilt University's Autonomic Dysfunction Center.

DISCLAIMER NOTICE: Publication by CurePSP of these studies is solely for research and scientific advancement purposes only, and their publication by CurePSP is neither an endorsement nor warranty by CurePSP of their results or conclusions.